Pfizer
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
27 Feb 2026
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease a
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
27 Feb 2026
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancer Pivotal results from the Phase 3 portion with mFOLFOX6 of the BREAK
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
17 Feb 2026
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E -mutant metastatic colorectal cancer Results
FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
06 Feb 2026
Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMP
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
06 Feb 2026
Program offers significant savings on over 30 brands spanning women’s health, migraine, arthritis, rare disease and more Affirms Pfizer’s commitment to reduce drug costs for millions of Americans thro
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
03 Feb 2026
VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3 Study met primary endpoint of statistically significant weight
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
12 Jan 2026
Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevaci
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
19 Dec 2025
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpo
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
17 Dec 2025
TOKYO AND NEW YORK, December 17, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an inte
PADCEV® Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
17 Dec 2025
TOKYO AND NEW YORK, December 17, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an inte
Featured
Typewriters, the office machines that preceded computers
By Kiron Kasbekar | 10 Apr 2025
You see office tables today equipped with desktop computers or laptops. But think of the 1970s, and what would you have been seeing?
Wishful thinking about cars
By Kiron Kasbekar | 05 Apr 2025
Donald Trump may be many things, but a good economist he is not. Accustomed to dictating terms to people he has worked with,
The history of safety glass
By Kiron Kasbekar | 26 Mar 2025
You probably already knew that the world’s VIPs move around in cars with bullet-proof glass windscreen and windows. But did you know that ‘bulletproof glass’ is not really bulletproof?
German silver: used in cutlery, music, electricals - but it’s not silver
By Kiron Kasbekar | 20 Mar 2025
This material, which was first developed in China, not Germany, and is an alloy of copper, nickel and zinc, has lost its sheen in home uses, but finds favor in electrical engineering.
Pioneers – the Wrights and Glenn Curtiss launched the aircraft industry
By Kiron Kasbekar | 17 Mar 2025
First Orville and Wilbur Wright flew their plane, the ‘Wright Flyer’, from near a small town called Kitty Hawk. Then Glenn Curtiss built planes with a very different system of controls, which has lasted until now.
What do aircraft have in common with bicycles and motorcycles?
By Kiron Kasbekar | 17 Mar 2025
From chains and sprockets to direct drives—If someone asked you what aircraft have in common with bicycles and motorcycles, how would you respond?
Radar’s ancestors: From sound mirrors to modern detection technology
By Kiron Kasbekar | 11 Mar 2025
Radar has become a well-settled technology today, especially in the field of navigation.
Nokia Bell Labs: innovations in communication, computing, technology
By Omar Almeida | 08 Mar 2025
Bell Laboratories, or Bell labs, which has now become Nokia Bell Labs, is one of the most renowned research and development organizations in the history of science and technology.
Company story – Quaker Oats
By Kiron Kasbekar | 08 Mar 2024
Quaker Oats is a company whose products I remember from my childhood days. Years before a foreign exchange crisis caused the Indian government to impose curbs on consumer product imports, we used to see a host of foreign brands in the Indian market. Including Quaker Oats, which I remember eating when I was a child, and which has been available for the past two decades or more.
